Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 4/2013

01-08-2013 | Original Article

Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study

Authors: Takuya Koie, Chikara Ohyama, Yasuhiro Hashimoto, Shingo Hatakeyama, Hayato Yamamoto, Takahiro Yoneyama, Noritaka Kamimura

Published in: International Journal of Clinical Oncology | Issue 4/2013

Login to get access

Abstract

Background

Neoadjuvant cisplatin-based chemotherapy for patients with muscle-invasive bladder cancer (BC) has better survival benefit than radical cystectomy (RC) alone. However, optimal dosing schedule, including drug selection, number of cycles, and interval between chemotherapy and cystectomy, as well as acceptable regimens remain to be established. We conducted a single-arm prospective study to evaluate efficacy and safety of neoadjuvant gemcitabine plus carboplatin (GCarbo) chemotherapy followed by immediate RC in patients with muscle-invasive BC, including cisplatin-unfit patients.

Methods

Between March 2005 and June 2011, we enrolled 116 patients with histologically proven muscle-invasive BC, including 44 % of the patients who were identified as cisplatin-unfit. All participants received two courses of GCarbo therapy, gemcitabine 800 mg/m2 administered on days 1, 8, and 15 and carboplatin with an area under the curve of four (AUC 4) administered on day 2. RC and bilateral pelvic lymphadenectomy were performed approximately within a month after cessation of chemotherapy. The primary endpoint was pT0 in the cystectomy specimen. Secondary endpoints were overall response rate, overall (OS) and disease-free survival (DFS), and toxicity. Survival after cystectomy was analyzed using the Kaplan–Meier method.

Results

The RC specimens of 28 (24.1 %) patients showed pT0. At a median follow-up period of 41 months, the OS and DFS rates were 89.7 and 86.3 %, respectively. No patients had grade 3/4 gastrointestinal toxicity or renal impairment.

Conclusions

Neoadjuvant GCarbo therapy followed by immediate RC is safe, even in cisplatin-unfit patients, and provides a favorable pathological cancer-free state. The single-arm single-institution study design and relatively short observation period were limitations of this study.
Literature
1.
Raghavan D, Shipley WU, Hall RR et al (1997) Biology and management of invasive bladder cancer. In: Raghavan D, Scher HI (eds) Principles and practice of genitourinary oncology. Lippincott-Ravel, Philadelphia, pp 281–298
2.
Ghonheim MA, El-Mekresh MM, Mokhtar AA et al (2000) A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int 85:811–816CrossRef
3.
Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Eng J Med 349:859–866CrossRef
4.
David KA, Milowsky MI, Ritchey J et al (2007) Low incidence of perioperative chemotherapy for stage III bladder cancer 1998–2003: a report from the National Cancer Data Base. J Urol 178:451–454CrossRefPubMed
5.
Loehrer P, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol 10:1066–1073PubMed
6.
Mamhmud S, Fong B, Fahmy N et al (2006) Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. J Urol 175:78–83CrossRef
7.
Weight CJ, Garcia JA, Hansel DE et al (2009) Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer 115:792–799CrossRefPubMed
8.
von der Masse H, Sengelov L, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multicenter, multinational, multicenter, phase III study. J Clin Oncol 18:3068–8077
9.
von der Masse H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608CrossRef
10.
Dash A, Pettus JA IV, Herr HW et al (2008) A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 113:24712477CrossRef
11.
International Collaboration of Trial on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177CrossRef
12.
Bellmunt J, Ribas A, Eres N et al (1997) Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966–1972CrossRefPubMed
13.
Bamias A, Moulopoulos LA, Koutras A et al (2006) The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer 106:297–303CrossRefPubMed
14.
Galsky MD, Hahn NM, Rosenberg G et al (2011) Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol 14:2432–2438CrossRef
15.
Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756PubMed
16.
Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York
17.
Life expectancy and mortality (2011). In: World health statistics 2011, World health organization press, Geneva, pp 45–55
18.
Koie T, Yamamoto H, Okamoto A et al (2009) Feasibility and efficacy of gemcitabine and carboplatin neoadjuvant chemotherapy in muscle-invasive bladder cancer. J Clin Oncol 27(suppl):e16100
19.
Ranaldi M, Crino L, Scagliotti GV et al (2000) A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Ann Oncol 11:1295–1300CrossRef
20.
Para HS, Caviuna R, Latteri F et al (2004) Tree-week versus four-week schedule of cisplatin and gemcitabine: results of randomized phase II study. Ann Oncol 13:1080–1086CrossRef
21.
Ando Y, Minami H, Saka H et al (1997) Adjustment of creatinine clearance improves accuracy of Calvert’s formula for carboplatin dosing. Br J Cancer 76:1067–1071CrossRefPubMed
22.
Advanced Bladder Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361:1927–1934CrossRef
23.
No authors listed (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. International collaboration of trialists. Lancet 354:533–540CrossRef
24.
Scosyrev E, Messing EM, van Wijngaarden E et al (2012) Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer 118:72–81CrossRefPubMed
25.
Shannon C, Crombie C, Brooks A et al (2001) Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic feature. Ann Oncol 12:947–952CrossRefPubMed
26.
Linardou H, Aravantinos G, Efstathiou E et al (2004) Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic co-operative oncology group. Urology 64:479–484CrossRefPubMed
Metadata
Title
Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study
Authors
Takuya Koie
Chikara Ohyama
Yasuhiro Hashimoto
Shingo Hatakeyama
Hayato Yamamoto
Takahiro Yoneyama
Noritaka Kamimura
Publication date
01-08-2013
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-012-0447-z

Other articles of this Issue 4/2013

International Journal of Clinical Oncology 4/2013 Go to the issue

Original Article

The clinical features and prognosis of phyllodes tumors: a single institution experience in Taiwan

Original Article

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

Original Article

Cetuximab-induced skin reactions are suppressed by cigarette smoking in patients with advanced colorectal cancer

Original Article

Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer

Original Article

Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients

Original Article

Polymorphism of A118G in μ-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits